
Seminate   Poject Title   1990/05   2000			Project Site	Date of First	
1,5W07009	Ethics	Duning & Tible	R&D	Patient	Development Mark on Development for Delevi
		•	1		1
MCANAR2 - IRAN OMERICA's vs Duzarahine in NRAS mutation   27/01/2014   22/08/2014   Reasons for delay rest with the Sponsor   3/01/2014   22/08/2014   1/02/2014   Reasons for delay rest with the Sponsor   3/01/2014   22/08/2014   1/02/2014   Reasons for delay rest with both sponsor   2/01/2014   1/02/2014   Reasons for delay rest with both sponsor   2/01/2014   1/02/2014					
3,00,000.00	13/SC/0452	,	23/01/2014	14/03/2014	Benchmark met
3/(4)/2015   1/(	13/10/0720		21/01/2014	22/08/2014	Reasons for delay rest with the Sponsor
20,000,000,000,000,000,000,000,000,000,					*
2011/1903   2016/5014 and Trust   2016/5016   Pareletes for Neonstal Transplasion Study   17/00/2004   18/06/5014   Reasons for delay rest with the Sponsor Continuation Study of Prophylactic Bax 855 in PTP with   17/00/2004   18/06/5014	13/ WA/0203	cent //1 (Endomethosis related pain)	30/01/2014	11/03/2014	
Description   Platelets for Neonatal Transfusion Study   Propelylatic Back & S5 in PTP with   17/02/2014   13/03/2014   Benchmark met   13/03/2014	12/EE/0071	CCRN 923 (Ascites)	20/11/2013	20/05/2014	-
Annix   Continuation Study of Prophylaciae Bax 355 in PTP with   17/02/2014   13/03/2014   Benchmark met   13/03/2014   Benchmark met   13/03/2014   Benchmark met   24/03/2014   13/03/2014   Benchmark met   24/03/2014   13/03/2014   Benchmark met   24/03/2014   13/03/2014   Benchmark met   24/03/2014   13/03/2014					
Althor/tools   Asamophila A   17/02/2014   31/03/2014   Benchmark met	10/H0306/61	Platelets for Neonatal Transfusion Study	17/02/2014	08/06/2014	Reasons for delay rest with the Sponsor
		Continuation Study of Prophylactic BAX 855 in PTP with			
MCRN2937 (ALS-8176-593) Developing a new drug to treat   24/02/2014   26/02/2014   27/02/2014	14/NW/0001	Haemophilia A	17/02/2014		
AMM/0031   infants hospitalised with RSV infection   24/02/2014   25/11/2014 control of the Sponsor and Trist   3/3/W/3008   5/4/ROCAN: Saracatrib and docetaxel in met, cast-ref prostate   10/03/2014   23/04/2014   Benchmark met   3/3/W/3008   23/04/2014   Senchmark met   21/03/2014   23/04/2014   Senchmark met   20/03/2014   Senchmark met	13/NW/0002	- 11	06/02/2014	05/03/2014	Benchmark met
13,00,000   CoolKenona   21,00,20014   19,00,32014   19,					•
SAPROCAN: Saractinib and docetaxel in met, cast-ref prostate   10/03/2014   23/04/2014   Benchmark met   3/04/2019   GOZ   G					·
13/14/2013   cancer   10/03/2014   23/04/2014   Benchmark met   19/02/2014   23/04/2014   Benchmark met   23/05/2014   Benchmark met   Benchmark met   23/05/2014   Benchmark met   Benchmark me	13/SW/0300		21/02/2014	19/03/2014	Benchmark met
3/3/H/0029   GO2   Moltrentan in Eisenmenger Syndrome AC-055-305   28/02/2014   28/02/2014   29/02/2014   2		•			
MAESTRO: Macternal in Esemenger Syndrome AC-055-305   28/02/2014   10/03/2014   1					
3,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0	13/YH/0229		19/02/2014	23/04/2014	
Main	12/10/0161		29/02/2014		· ·
M12-813: Elagolis in Premorpassual Women with Heavy   17/03/2014   22/05/2014   Benchmark met   Delays due to external factors outside the   03/07/2014   Control of the Sponsor and Trust   Reasons for delay rest with both sponsor and Trust   17/03/2014   17/03/2014   17/03/2014   17/03/2014   Reasons for delay rest with both sponsor and Trust   17/03/2014   17/03/2014   17/03/2014   Reasons for delay rest with both sponsor and Trust   17/03/2014   17/03/2014   Reasons for delay rest with the Sponsor Delays due to external factors outside the control of the Sponsor and Trust   17/03/2014   17/03/2014   Reasons for delay rest with the Sponsor Delays due to external factors outside the control of the Sponsor and Trust   17/03/2014   Reasons for delay rest with the Sponsor		, ,			-
	14/1/0001	,	11/03/2014	19/03/2014	benchinark met
SAMS/0304   EVARREST (The Fibrin Pad CV Phase III Study)   17/03/2014   03/07/2014   control of the Sponsor and Trust   20/03/2014   14/07/2014   Reasons for delay rest with both sponsor and Trust   20/03/2014   14/07/2014   Reasons for delay rest with both sponsor and Trust   20/03/2014   14/07/2014   Reasons for delay rest with the Sponsor and Trust   20/03/2014   20/05/2014	13/FF/0377		13/03/2014	22/05/2014	Benchmark met
17/03/2014   03/07/2014   03/	13/11/03//	Wellstrain Dieealing Associated with Oterine Fibrolas	13/03/2014	22/03/2014	
Section   Sect	13/WS/0304	EVARREST (The Fibrin Pad CV Phase III Study)	17/03/2014	03/07/2014	•
	13/113/0301	ZVI III ZZVI (TIZ TIZ TIZ TIZ ZZ TIZ ZZ TIZ ZZ Z	27,00,201	03/01/2011	•
12/LO/10178   MUK five   20/03/2014   14/07/2014   Reasons for delay rest with the Sponsor Delays due to external factors outside the Control of the Sponsor and Trust   11/03/2014   26/03/2014   20/05/2014   Reasons for delay rest with the Sponsor Delays due to external factors outside the Control of the Sponsor and Trust   25/03/2014   20/05/2014   20	13/SW/0186	EFFECT - Efficacy of Fluticasone/Formoterol in COPD Treatment	11/03/2014		-
1,04/2010   MCRN222 (MCI-196-E14)   11/03/2014   Control of the Sponsor and Trust					
11/03/2014   Control of the Sponsor and Trust	12/LO/1078	MUK five	20/03/2014	14/07/2014	Reasons for delay rest with the Sponsor
22/10/1717   ZEBRA   26/03/2014   Reasons for delay rest with the Sponsor   26/03/2014   20/05/2014   Reasons for delay rest with the Sponsor   26/03/2014   20/05/2014   Reasons for delay rest with the Sponsor   26/03/2014   20/05/2014   Reasons for delay rest with the Sponsor   28/03/2014   20/05/2014   Reasons for delay rest with the Sponsor   28/03/2014   20/05/2014   Reasons for delay rest with the Sponsor   28/03/2014   28/07/2014   Reasons for delay rest with the Sponsor   28/03/2014   28/07/2014   Reasons for delay rest with the Sponsor   28/03/2014   28/07/2014   Reasons for delay rest with the Sponsor   28/03/2014   28/07/2014   Reasons for delay rest with the Sponsor   28/03/2014   28/07/2014   Reasons for delay rest with the Sponsor   28/03/2014   28/07/2014   Reasons for delay rest with the Sponsor   28/03/2014   28/07/2014   28/07/2014   Reasons for delay rest with the Sponsor   28/03/2014   28/07/20					
22/55/0138   RESTART study   26/03/2014   20/05/2014	13/YH/0020	MCRN222 (MCI-196-E14)	11/03/2014		control of the Sponsor and Trust
22/55/0138   RESTART study   26/03/2014   20/05/2014					
Vasopressin vs Noradrenaline as Initial therapy in Septic Shock   O3/04/2014   O5/06/2014   Benchmark met	12/LO/1717	ZEBRA	26/03/2014		
(Vanish)	12/SS/0138	·	26/03/2014	20/05/2014	Benchmark met
3/NH/0152   FIGARO					
ACORN - Improving diagnosis with endocervical curettage and   A/SW/0028   ACORN - Improving diagnosis with endocervical curettage and   A/SW/0028   P16 staining   O7/04/2014   O6/05/2014   Benchmark met   O7/04/2014   23/05/2014   Benchmark met   O7/04/2014   23/05/2014   Benchmark met   O7/04/2014	<u> </u>	, ,			
ACORN - Improving diagnosis with endocervical curettage and   A/SW/0028   P16 staining   O7/04/2014   O6/05/2014   Benchmark met   23/05/2014   Benchmark met	13/NE/0049	MCRN224 (BAY 94-9027)	28/03/2014	03/06/2014	Benchmark met
ACORN - Improving diagnosis with endocervical curettage and   A/SW/0028   P16 staining   O7/04/2014   O6/05/2014   Benchmark met   23/05/2014   Benchmark met	42 // /0452	510400	24 /02 /204 4	20/07/2044	
	13/YH/0152		21/03/2014	28/07/2014	Reasons for delay rest with the Sponsor
3/SC/0111   FOCUS 4   09/04/2014   23/05/2014   Benchmark met	14/514/0029		07/04/2014	06/05/2014	Panchmark mat
		<u> </u>			
JETREA FIRSTLINE (ALCON) - Assessment of Patients Treated   15/04/2014   03/06/2014   Benchmark met   12/U0/0145   DRN 840 (CLEOPATRA)   29/04/2014   04/07/2014   Benchmark met   29/04/2014   Delays due to external factors outside the   06/10/2014   O6/10/2014					
A/SC/0100   With JETREA® for Vitreomacular Traction   15/04/2014   03/06/2014   Benchmark met	13/11/0143		02/04/2014	25/05/2014	Deficilitate frice
22/LO/0145   DRN 840 (CLEOPATRA)   29/04/2014   04/07/2014   Benchmark met   Delays due to external factors outside the   30/04/2014   23/05/2014   21/08/2014   Control of the Sponsor and Trust   11/05/2014   23/05/2014   21/08/2014   Control of the Sponsor and Trust   12/05/2014   21/08/2014   21/08/2014   Delays due to external factors outside the   20/04/2014   23/05/2014   Delays due to external factors outside the   20/04/2014   21/08/2014   Delays due to external factors outside the   20/04/2014   Control of the Sponsor and Trust   21/05/2014   Delays due to external factors outside the   20/04/2014   Control of the Sponsor and Trust   21/05/2014   Delays due to external factors outside the   20/04/2014   Control of the Sponsor and Trust   21/05/2014   Delays due to external factors outside the   20/04/2014   Control of the Sponsor and Trust   21/05/2014   Delays due to external factors outside the   20/04/2014   Control of the Sponsor and Trust   21/05/2014   Delays due to external factors outside the   20/05/2014   Delays due to exter	14/SC/0100		15/04/2014	03/06/2014	Benchmark met
TRIOC  A/SW/0079  CCRN - 3308 The DEFLECT III Trial  TRIOC  COAST BAY73-4506/15983: Regorafenib as adjuvant therapy for resected liver metastases  A/LO/0036  NCRN2555 - TOWER Study (00103311)  PREVENTIC (Preoperative intravenous iron to treat anaemia in major surgery)  Alight (AMD light trial)  A/CRN2280 Sativex Severe Spasticity (GWSP08258)  A/CRVA/0230  ROCS: Radiotherapy after Oesophageal Cancer Stenting Study  ROCS: Radiotherapy after Oesophageal Cancer Stenting Study  ROCS: Radiotherapy after Oesophageal Cancer Stenting Study  Brown A/DRO STOWN ROCS Study of Sativex in Patients with Recurrent Glioblastoma  Brown A/DRO PRE Filid Rangement in 10-155% BSA scalds  A/CRVA/0007  MCRN2368 UCB PRA Epilepsy Lacosamide SP0969  A/CRVA/0004  MCRN2368 UCB PRA Epilepsy Lacosamide SP0969  A/CRVA/0004  Delays due to external factors outside the control of the Sponsor and Trust Polyay due to external factors outside the control of the Sponsor and Trust Polyay due to external factors outside the control of the Sponsor and Trust Polyay due to external factors outside the control of the Sponsor and Trust Polyay due to external factors outside the control of the Sponsor and Trust Polyay due to external factors outside the control of the Sponsor and Trust Polyay due to external factors outside the control of the Sponsor and Trust Polyay due to external factors outside the control of the Sponsor and Trust Polyay due to external factors outside the control of the Sponsor and Trust Polyay due to external factors outside the control of the Sponsor and Trust Polyay due to external factors outside the control of the Sponsor and Trust Polyay due to external factors outside the control of the Sponsor and Trust Polyay due to external factors outside the control of the Sponsor and Trust Polyay due to external factors outside the control of the Sponsor and Trust Polyay due to external factors outside the control of the Sponsor and Trust Polyay due to external factors outside the control of the Sponsor and Trust Polyay due to external fact					
TRIOC   30/04/2014   06/10/2014   control of the Sponsor and Trust	, -, -			. , . , .	
COAST BAY73-4506/15983: Regorafenib as adjuvant therapy for resected liver metastases 12/05/2014 21/08/2014 Control of the Sponsor and Trust 29/04/2014 Reasons for delay rest with the Trust 12/05/2014 21/08/2014 Control of the Sponsor and Trust 29/04/2014 Reasons for delay rest with the Trust 21/05/2014 Control of the Sponsor and Trust 29/04/2014 Reasons for delay rest with the Sponsor and Trust 29/04/2014 Control of the Sponsor and Trust 29/04/2014 Control of the Sponsor and Trust 29/04/2014 Control of the Sponsor and Trust 20/05/2014 Control of the Sponsor	GTAC182	TRIOC	30/04/2014	06/10/2014	
12/05/2014   21/08/2014   21/	14/SW/0079	CCRN - 3308 The DEFLECT III Trial	11/05/2014	23/05/2014	Benchmark met
ALIA/DO036 NCRN2555 - TOWER Study (00103311)  PREVENTT (Preoperative intravenous iron to treat anaemia in major surgery)  Alight (AMD light trial)		COAST BAY73-4506/15983: Regorafenib as adjuvant therapy for			Delays due to external factors outside the
PREVENTT (Preoperative intravenous iron to treat anaemia in major surgery)  Alight (AMD light trial)  PEPtalk 2  12/05/2014  MCRN2280 Sativex Severe Spasticity (GWSP08258)  TOMP  Alight (AMO Peptalk 2)  TOMP  T	13/NW/0705		12/05/2014	21/08/2014	•
L2/EE/0445 major surgery)  Alight (AMD light trial)  12/05/2014  Alight (AMD light trial)  12/05/2014  Delays due to external factors outside the control of the Sponsor and Trust  13/YH/0201  MCRN2280 Sativex Severe Spasticity (GWSP08258)  MCRN2280 Sativex Severe Spasti	14/LO/0036		29/04/2014		•
Alight (AMD light trial)  12/05/2014  12/05/2014  Delays due to external factors outside the control of the Sponsor and Trust  13/VH/0201  MCRN2280 Sativex Severe Spasticity (GWSP08258)  MCRN2368 UCB PRA Epilepsy Lacosamide SP0969  MCRN2368					
Delays due to external factors outside the control of the Sponsor and Trust  13/VH/0201 MCRN2280 Sativex Severe Spasticity (GWSP08258)  13/YH/0201 STOMP  12/WA/0230 ROCS: Radiotherapy after Oesophageal Cancer Stenting Study  GWCA1208 - Study of Sativex in Patients with Recurrent  GWCA1208 - Study of Sativex in Patients with Recurrent  GIoblastoma  12/NW/0827 Euro Ewing 2012  13/NE/0197 RDP Trial (Ranibizumab for DMO PRP trial)  10/H0203/70 Fluid Management in 10-15% BSA scalds  12/WH/0007 MCRN2368 UCB PRA Epilepsy Lacosamide SP0969  12/WS/0004 Odyssey OLE  12/OS/2014 Senchmark met  Delays due to external factors outside the control of the Sponsor and Trust  Delays due to external factors outside the control of the Sponsor and Trust  Delays due to external factors outside the control of the Sponsor and Trust  Delays due to external factors outside the control of the Sponsor and Trust	12/EE/0445				
12/O5/2014 control of the Sponsor and Trust  13/YH/0201 MCRN2280 Sativex Severe Spasticity (GWSP08258)  14/YH/0290 STOMP  15/WA/0230 ROCS: Radiotherapy after Oesophageal Cancer Stenting Study  15/WA/0230 GWCA1208 - Study of Sativex in Patients with Recurrent  15/YH/0126 Glioblastoma  16/O5/2014 O8/O9/2014 Benchmark met  17/O7/2014 Benchmark met  18/YH/0126 Glioblastoma  18/YH/0126 Glioblastoma  18/YH/0127 Euro Ewing 2012  18/YH/0197 RDP Trial (Ranibizumab for DMO PRP trial)  18/YH/0203/70 Fluid Management in 10-15% BSA scalds  18/YH/0007 MCRN2368 UCB PRA Epilepsy Lacosamide SP0969  18/WS/0004 Odyssey OLE  18/WS/0004 STOMP  18/O5/2014 O8/O9/2014 Reasons for delay rest with the Sponsor O9/O6/2014 O8/O9/2014 Reasons for delay rest with the Trust Delays due to external factors outside the control of the Sponsor and Trust Delays due to external factors outside the Control of the Sponsor and Trust Delays due to external factors outside the Delays due to external	13/NW/0609	Alight (AMD light trial)	12/05/2014	09/07/2014	
MCRN2280 Sativex Severe Spasticity (GWSP08258)  06/05/2014  23/09/2014 Reasons for delay rest with the Sponsor  01/05/2014  03/09/2014 Reasons for delay rest with the Sponsor  01/05/2014  03/09/2014 Reasons for delay rest with the Sponsor  12/WA/0230 ROCS: Radiotherapy after Oesophageal Cancer Stenting Study  GWCA1208 - Study of Sativex in Patients with Recurrent  GIoblastoma  06/06/2014  16/07/2014 Benchmark met  12/NW/0827 Euro Ewing 2012  09/06/2014  08/09/2014 Reasons for delay rest with the Sponsor  13/NE/0197 RDP Trial (Ranibizumab for DMO PRP trial)  10/H0203/70 Fluid Management in 10-15% BSA scalds  12/06/2014  12/06/2014  12/06/2014  12/06/2014  12/06/2014  12/06/2014  12/06/2014  13/07/2014 Benchmark met  Delays due to external factors outside the control of the Sponsor and Trust  Delays due to external factors outside the Delays due to external factors outside the	12/10/255	DEDI-III 2	40/05/555		
STOMP  O1/05/2014  O3/09/2014 Reasons for delay rest with the Sponsor  12/WA/0230  ROCS: Radiotherapy after Oesophageal Cancer Stenting Study  GWCA1208 - Study of Sativex in Patients with Recurrent  Glioblastoma  O6/06/2014  O9/06/2014  O8/09/2014  Reasons for delay rest with the Sponsor  16/07/2014  Benchmark met  06/06/2014  O8/09/2014  Reasons for delay rest with the Sponsor  13/NE/0197  RDP Trial (Ranibizumab for DMO PRP trial)  O9/06/2014  O9/06/2014  O5/09/2014  Reasons for delay rest with the Trust  10/H0203/70  Fluid Management in 10-15% BSA scalds  12/06/2014  Delays due to external factors outside the control of the Sponsor and Trust  Odlyssey OLE  O3/09/2014  O3/09/2014  O8/09/2014	13/10/0551	PEPLAIK Z	12/05/2014		control of the Sponsor and Trust
STOMP  O1/05/2014  O3/09/2014 Reasons for delay rest with the Sponsor  12/WA/0230  ROCS: Radiotherapy after Oesophageal Cancer Stenting Study  GWCA1208 - Study of Sativex in Patients with Recurrent  Glioblastoma  O6/06/2014  O9/06/2014  O8/09/2014  Reasons for delay rest with the Sponsor  16/07/2014  Benchmark met  06/06/2014  O8/09/2014  Reasons for delay rest with the Sponsor  13/NE/0197  RDP Trial (Ranibizumab for DMO PRP trial)  O9/06/2014  O9/06/2014  O5/09/2014  Reasons for delay rest with the Trust  10/H0203/70  Fluid Management in 10-15% BSA scalds  12/06/2014  Delays due to external factors outside the control of the Sponsor and Trust  Odlyssey OLE  O3/09/2014  O3/09/2014  O8/09/2014	12 /VH /0204	MCDN2290 Cativoy Covers Casatisity (CN/CD00250)	00/05/2011	22/00/2011	Descent for deleverent with the Consess
ROCS: Radiotherapy after Oesophageal Cancer Stenting Study GWCA1208 - Study of Sativex in Patients with Recurrent Glioblastoma Glioblas	13/11/0201	ivichinzzau Sativex Severe Spasticity (GWSPU8258)	00/05/2014	23/09/2014	neasons for delay rest with the Sponsor
ROCS: Radiotherapy after Oesophageal Cancer Stenting Study GWCA1208 - Study of Sativex in Patients with Recurrent Glioblastoma Glioblas	11 /VH /0200	STOMP	01/05/2014	02/00/2014	Reasons for delay rost with the Spanser
GWCA1208 - Study of Sativex in Patients with Recurrent Glioblastoma  06/06/2014  16/07/2014  Benchmark met  12/NW/0827  Euro Ewing 2012  09/06/2014  08/09/2014  Reasons for delay rest with the Sponsor  09/06/2014  05/09/2014  Reasons for delay rest with the Trust  10/H0203/70  Fluid Management in 10-15% BSA scalds  12/06/2014  12/06/2014  Delays due to external factors outside the control of the Sponsor and Trust  14/WS/0004  Odyssey OLE  06/06/2014  08/09/2014  08/09/2014  Reasons for delay rest with the Trust  Delays due to external factors outside the control of the Sponsor and Trust  Delays due to external factors outside the control of the Sponsor and Trust  Delays due to external factors outside the control of the Sponsor and Trust	11/11/0230	5101111	01/03/2014	03/03/2014	neasons for acidy rest with the sponsor
GWCA1208 - Study of Sativex in Patients with Recurrent Glioblastoma  06/06/2014  16/07/2014  Benchmark met  12/NW/0827  Euro Ewing 2012  09/06/2014  08/09/2014  Reasons for delay rest with the Sponsor  09/06/2014  05/09/2014  Reasons for delay rest with the Trust  10/H0203/70  Fluid Management in 10-15% BSA scalds  12/06/2014  12/06/2014  Delays due to external factors outside the control of the Sponsor and Trust  14/WS/0004  Odyssey OLE  06/06/2014  08/09/2014  08/09/2014  Reasons for delay rest with the Trust  Delays due to external factors outside the control of the Sponsor and Trust  Delays due to external factors outside the control of the Sponsor and Trust  Delays due to external factors outside the control of the Sponsor and Trust	12/WA/0230	ROCS: Radiotherapy after Oesonhageal Cancer Stenting Study	09/06/2014	17/07/2014	Benchmark met
13/YH/0126 Glioblastoma 06/06/2014 16/07/2014 Benchmark met  12/NW/0827 Euro Ewing 2012 09/06/2014 08/09/2014 Reasons for delay rest with the Sponsor 09/06/2014 05/09/2014 Reasons for delay rest with the Sponsor 09/06/2014 05/09/2014 Reasons for delay rest with the Trust 12/06/2014 12/06/2014 12/06/2014 Reasons for delay rest with the Trust 12/06/2014 12/06/2014 12/06/2014 Delays due to external factors outside the control of the Sponsor and Trust 14/WS/0004 Odyssey OLE 30/05/2014 31/07/2014 Benchmark met Delays due to external factors outside the Delays due to external factors outside the			55/00/2014	1,70,72014	Sensimurk met
L2/NW/0827 Euro Ewing 2012 09/06/2014 08/09/2014 Reasons for delay rest with the Sponsor 09/06/2014 05/09/2014 Reasons for delay rest with the Sponsor 09/06/2014 05/09/2014 Reasons for delay rest with the Trust 09/06/2014 22/10/2014 Reasons for delay rest with the Trust 09/06/2014 22/10/2014 Reasons for delay rest with the Trust 09/06/2014 09/06/2014 09/09/2014 Reasons for delay rest with the Trust 09/06/2014 09/09/2014 Reasons for delay rest with the Trust 09/06/2014 09/09/2014 Reasons for delay rest with the Trust 09/06/2014 09/09/2014 Reasons for delay rest with the Trust 09/09/2014 09/09/2014 Reasons for delay rest with the Trust 09/09/2014 09/09/2014 Reasons for delay rest with the Trust 09/09/2014 09/09/2014 Reasons for delay rest with the Trust 09/09/2014 09/09/2014 Reasons for delay rest with the Trust 09/09/2014 09/09/2014 Reasons for delay rest with the Trust 09/09/2014 09/09/2014 Reasons for delay rest with the Trust 09/09/2014 09/09/2014 Reasons for delay rest with the Trust 09/09/2014 09/09/2014 Reasons for delay rest with the Trust 09/09/2014 09/09	13/YH/0126	The state of the s	06/06/2014	16/07/2014	Benchmark met
13/NE/0197   RDP Trial (Ranibizumab for DMO PRP trial)   09/06/2014   05/09/2014   Reasons for delay rest with the Trust   12/06/2014   22/10/2014   Reasons for delay rest with the Trust   22/10/2014   Reasons for delay rest with the Trust   Delays due to external factors outside the control of the Sponsor and Trust   24/WS/0004   00/2014   0	, , , = ==		.,,	,: ,====:	
13/NE/0197   RDP Trial (Ranibizumab for DMO PRP trial)   09/06/2014   05/09/2014   Reasons for delay rest with the Trust   12/06/2014   22/10/2014   Reasons for delay rest with the Trust   22/10/2014   Reasons for delay rest with the Trust   Delays due to external factors outside the control of the Sponsor and Trust   24/WS/0004   00/2014   0	12/NW/0827	Euro Ewing 2012	09/06/2014	08/09/2014	Reasons for delay rest with the Sponsor
12/06/2014 22/10/2014 Reasons for delay rest with the Trust Delays due to external factors outside the control of the Sponsor and Trust Odyssey OLE 30/05/2014 31/07/2014 Reasons for delay rest with the Trust Delays due to external factors outside the control of the Sponsor and Trust 30/05/2014 31/07/2014 Benchmark met Delays due to external factors outside the	13/NE/0197				
Delays due to external factors outside the control of the Sponsor and Trust  14/WS/0004 Odyssey OLE 30/05/2014 31/07/2014 Benchmark met  Delays due to external factors outside the control of the Sponsor and Trust  30/05/2014 31/07/2014 Benchmark met  Delays due to external factors outside the	10/H0203/70	· · · · · · · · · · · · · · · · · · ·			
4/WS/0004 Odyssey OLE 30/05/2014 31/07/2014 Benchmark met Delays due to external factors outside the					
Delays due to external factors outside the	14/YH/0007	MCRN2368 UCB PRA Epilepsy Lacosamide SP0969	12/06/2014		control of the Sponsor and Trust
	14/WS/0004	Odyssey OLE	30/05/2014	31/07/2014	
23/SC/0557 THAPCA-IH-UK 17/06/2014 control of the Sponsor and Trust					
	13/SC/0557	THAPCA-IH-UK	17/06/2014		control of the Sponsor and Trust

		Project Site	Date of First	
Ethics		R&D	Patient	
Committee Ref	•	Submission	Consented	Benchmark Met or Reason for Delay
	Pharmacokinetic variation and toxicity in Ewing's sarcoma (PK		/ /	Delays due to external factors outside the
	2013 01)	20/06/2014		control of the Sponsor and Trust
	Apposition V NIMRAD (NIMorazole/placebo plus RADiotherapy in head and	23/06/2014		Benchmark met
	, , , , , , , , , , , , , , , , , , , ,	01/07/2014		Delays due to external factors outside the
	neck cancer) WA29231- LONG-TERM EXTENSION STUDY TO EVALUATE THE	01/07/2014	18/12/2014	control of the Sponsor and Trust
	SAFETY AND EFFICACY OF SUBCUTANEOUS TOCILIZUMAB IN			
	PATIENTS WITH POLYARTICULAR-COURSE AND SYSTEMIC			
	JUVENILE IDIOPATHIC ARTHRITIS	11/06/2014	16/07/2014	Benchmark met
14/11/0122	30 VERNEE ISION ANTHONIONINI	11/00/2014	10/07/2014	Delays due to external factors outside the
13/LO/0716	CCRN 2159 (Uveitis)	25/06/2014		control of the Sponsor and Trust
		-,,		Delays due to external factors outside the
13/LO/0717	CL3-78989-006. EYEGUARD-C study	25/06/2014	,	control of the Sponsor and Trust
	Study of efficacy and safety of nilotinib in paediatric CML			Delays due to external factors outside the
13/LO/1608	patients	07/07/2014	16/12/2014	control of the Sponsor and Trust
				Delays due to external factors outside the
	NCRN3025 - GDC-0199 in CLL (GO28667)	16/07/2014	22/10/2014	control of the Sponsor and Trust
	3H (Hemodiafiltration, Heart and Heights) study	28/07/2014	01/09/2014	Benchmark met
	InterAACT - A Multicentre Randomised Phase II Advanced Anal			Delays due to external factors outside the
	Cancer Trial	14/08/2014		control of the Sponsor and Trust
	EORTC protocol 26101	19/08/2014	15/09/2014	Benchmark met
	ABC-06: ASC alone or with mFOLFOX for advanced biliary tract	20/00/2044	00/40/2044	
13/NW/0702	cancer	20/08/2014	08/10/2014	Benchmark met
14/NN4/0000	ICO COLITIC	26/08/2014		December for delay rest with the Consess
	GO-COLITIS	26/08/2014 26/08/2014		Reasons for delay rest with the Sponsor Benchmark met
· ·	Predicting Language Outcome & Recovery after Stroke CLARITY	28/08/2014		Benchmark met
14/10/0203	CLARITI	28/08/2014	17/10/2014	Reasons for delay rest with both sponsor
13/EM/0395	Treatment of Advanced Glaucoma Study (TAGS)	04/09/2014		and Trust
	The effect of Plasma Rich in Growth Factors (PRGF) on	0 1,03,201		4.14
	periodontal tissue regeneration	28/08/2014	01/10/2014	Benchmark met
	NCRN - 2890: Quizartinib (AC220) Monotherapy vs. Salvage			Delays due to external factors outside the
14/EM/0130	Chemotherapy	15/09/2014		control of the Sponsor and Trust
				Delays due to external factors outside the
13/EE/0367	CCRN 2215 (Crohn's)	05/09/2014	17/12/2014	control of the Sponsor and Trust
				Reasons for delay rest with both sponsor
-, ,	15961 GadaCAD1	18/09/2014		and Trust
	The SNIFFLE 2 Study	29/09/2014		Benchmark met
	The BASICS Trial	03/10/2014		Benchmark met
, ,	RVENCH SWITCH	29/09/2014		Benchmark met
· ·		14/10/2014 01/10/2014		Benchmark met Benchmark met
· · ·	Group B streptococcus Immunisation Attitudes SWIFFT Trial	04/09/2014		Benchmark met
13/11/0134	SWILL IIIG	04/03/2014	12/11/2014	Deficilitate filet
14/NS/0089	Hip 'OP	17/10/2014		Reasons for delay rest with the Sponsor
2.7.1.07.0003		17/10/2011		reasons for acidy rest men the sponsor
	CONCEPT: A Phase II pilot study of 3 weekly Cabazitaxel versus			
	weekly Paclitaxel chemotherapy in the first line treatment of			
14/SC/0221	Her2 negative metastatic breast cancer (mBC)	21/10/2014	18/12/2014	Benchmark met
	AZD9291 v chemotherapy in NSCLC, following EGFR TKI therapy			
14/EE/1063	(AURA3)	29/10/2014		70 days not yet reached
	An Open-Label, Phase 1, Dose Escalation Study of MLN2480 in			
	Patients with Relapsed or Refractory Solid Tumors Followed by a			
	Dose Expansion Phase in Patients With Unresectable Melanoma.	03/11/2014		Benchmark met
	ROCSS	13/11/2014		Benchmark met
	OTO-104 in Meniere's Disease  The effect of Plasma Rich in Crouth Factors (RRCF) on the	13/11/2014	1//12/2014	Benchmark met
	The effect of Plasma Rich in Growth Factors (PRGF) on the	02/11/2014	2//11/2014	Benchmark met
	treatment of dry sockets Robot Assisted Fracture Surgery (RAFS)	03/11/2014 12/11/2014		70 days not yet reached
	Circulating Neuroblastoma Tumour Cell Study	19/11/2014		70 days not yet reached
	The JANUS 1 Study Incyte INCB 18424362	20/11/2014		70 days not yet reached
2./30/1017		20,11,2014		. o days not yet redened
1	Adjunctive Steroid Combination in Ocular Trauma (ASCOT) Study	01/12/2014		70 days not yet reached
14/LO/1428		. ,,	1	
	CAIRO WPC: PROXY Study	18/12/2014		70 days not yet reached

## No of days to First Patient Consented

Projects have been colour coded to identify length of time from submission of an application to first patient consented Key: BLACK - No recruitment > 70 days , RED+ - Recruited > 100 days, RED - Recruited 71 - 100 days, GREEN - Recruited <70 days



## Reasons for Delays in First Patient Consented

Internal delay: delay due to UH Bristol Trust issue

Both internal and external delay: contributing factors for delay from both UH Bristol and external party, e.g. contract review External delay sponsor: examples include delayed site initiation visits, green light visit.

External delay protocol design: protocol stipulates that very rare patient group/low recruitment or other protocol design which means site is unable to reasonably expect to recruit within 70 days.

External delay University: any University involvement contributing to the delay-e.g. contract review

External delay other Trust: a delay caused by an external Trust e.g. reviewing contracts, delaying initiation.

 $\textit{External delay other: any other delays which fall outside the above categories and are due to factors external to the \textit{Trust}.}$ 

